Aplicación de un algoritmo genético que incorpora lógica difusa para la minimización del tiempo del proceso de corte de diferentes tipos de materia prima para la empresa confecciones taller 84

En el trabajo de grado se utilizó la aplicación de un algoritmo genético para la minimización del tiempo de proceso de corte para una empresa que confecciona dotaciones industriales. Dentro de la aplicación del algoritmo genético se implementó y desarrollo el concepto de lógica difusa mediante el cual variables borrosas como por ejemplo: la habilidad de los operarios, patrón de corte y la características del material se volvieron variables reales o crisp, las cuales afectan los tiempos de proceso del área de extendido y corte de la empresa de confecciones. El algoritmo genético que se utilizó fue el generado con el software R-studio el cual permitió el modelamiento del algoritmo incluyendo el método de fuzzyficación propuesto.In this undergraduate work was used the application of a genetic algorithm with the aim of minimize the cut process for a garment enterprise. Inside the application of the genetic algorithm, the concept of fuzzy logic was developed through the fuzzy variables like ability of workers, cut pattern and material characteristics, those facts affect the process times of the spread and cut process in the enterprise. The genetic algorithm used was developed by R-studio which permits modeled both the genetic algorithm and thefuzzy model.Ingeniero (a) IndustrialPregrad

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN